Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Quadruplet prolongs progression-free survival in newly diagnosed myeloma
Key clinical point: Carfilzomib plus cyclophosphamide, lenalidomide, and dexamethasone (KCRD) significantly prolonged progression-free survival (PFS), compared with cyclophosphamide-lenalidomide-dexamethasone (CRD) or cyclophosphamide-thalidomide-dexamethasone (CTD) in transplant-eligible patients with newly diagnosed multiple myeloma.
Major finding: The 3-year PFS rate was 64.5% in the KCRD arm and 50.3% in the CTD-CRD arms combined. The hazard ratio was 0.63 (P less than .0001).
Study details: A phase 3 trial of 1,056 patients with newly diagnosed myeloma who were eligible for transplant.
Disclosures: The trial is sponsored by University of Leeds in collaboration with Celgene, Merck Sharp & Dohme, and Amgen. Dr. Pawlyn reported relationships with Amgen, Celgene, and other companies.
Pawlyn C et al. IMW 2019, Abstract OAB-002.